Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

Pallawi Torka, Anthony Masaquel, Lourenia Cassoli, David Fox, Arliene Mangalindan, Ajay Major

Blood (2024) 144 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2024-198476

Published: 2024

Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2024-198451

Published: 2024

Journal Articles

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

David Fox, Fadoua El Moustaid, Anthony Masaquel, Katherine L Rosettie, Hazal Celik, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5027.

https://doi.org/10.1182/blood-2024-198461

Published: 2024

Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch

Blood (2024) 144 (Supplement 1): 782.

https://doi.org/10.1182/blood-2024-198414

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Zahra Mahmoudjafari, Jia Li, Eric Bercaw, Hélène Parisé, Katalin Bognar, Si-Tien Wang, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 7246.

https://doi.org/10.1182/blood-2023-174218

Published: 2023

Journal Articles

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Zahra Mahmoudjafari, Danilo Di Maio, Jia Li, Katherine L. Rosettie, Anthony Masaquel

Blood (2023) 142 (Supplement 1): 3703.

https://doi.org/10.1182/blood-2023-174918

Published: 2023

Journal Articles

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Justin Gatwood, Anthony Masaquel, Ryan Ross, Danny Sheinson, Farah Hossain, Jia Li, Cameron James, David Fox

Blood (2022) 140 (Supplement 1): 7906–7907.

https://doi.org/10.1182/blood-2022-157905

Published: 2022

Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen

Blood (2022) 140 (Supplement 1): 6645–6647.

https://doi.org/10.1182/blood-2022-157904

Published: 2022

Journal Articles

Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)

Rongrong Wang, Josh Roth, Carmen Ng, Farah Hossain, Jia Li, Anthony Masaquel

Blood (2021) 138 (Supplement 1): 3002.

https://doi.org/10.1182/blood-2021-146802

Published: 2021

Journal Articles

Factors Associated with Overall Survival in Follicular Lymphoma Patients Who Are Eligible for Maintenance Therapy

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Zachary Burningham, PhD, Catherine Li, PhD, Christina Young, MA, Anthony Masaquel, PhD MPH, Kevin Henderson, PharmD, MBA, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4159.

https://doi.org/10.1182/blood-2018-99-115722

Published: 2018

Journal Articles

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

Ahmad S Halwani, MD, Kelli M Rasmussen, MS, Vikas Patil, MS, Catherine Li, PhD, Christina Young, MA, Zachary Burningham, PhD, Mathias Schulz, MD MBA, Jia Li, PhD, Anthony Masaquel, PhD MPH, Mary Halloran, PharmD, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2018) 132 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2018-99-116695

Published: 2018

Journal Articles

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Mark Price, MA, MD, Arliene Ravelo, MPH, Elisa Weiss, PhD, Peggy Ann Torney, MS, Victor Gonzalez, MHC-LP, Maria Sae-Hau, PhD, Carol Mansfield, PhD, Eydith Comenencia-Ortiz, PhD, Miko Cunanan, BS, Anthony Masaquel, PhD MPH, Keith L Dawson, DNP

Blood (2018) 132 (Supplement 1): 5897.

https://doi.org/10.1182/blood-2018-99-115327

Published: 2018

Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD

Blood (2017) 130 (Supplement 1): 5603.

https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603

Published: 2017

Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 683.

https://doi.org/10.1182/blood.V130.Suppl_1.683.683

Published: 2017

Journal Articles

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

Ahmad S. Halwani, MD, Kelli Rasmussen, MS, Vikas Patil, MS, Zach Burningham, PhD, Clarke Low, MD, Carolina M Reyes, PhD, Anthony Masaquel, MPH, PhD, Kevin Henderson, PharmD, MBA, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD

Blood (2017) 130 (Supplement 1): 1489.

https://doi.org/10.1182/blood.V130.Suppl_1.1489.1489

Published: 2017

Journal Articles

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

Carol Mansfield, PhD, Anthony Masaquel, MPH, PhD, Jessie Sutphin, Elisa S Weiss, PhD, Meghan E. Gutierrez, Jennifer Wilson, Jia Li, PhD, Carolina Reyes, PhD

Blood (2016) 128 (22): 1239.

https://doi.org/10.1182/blood.V128.22.1239.1239

Published: 2016

Journal Articles

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Gregory F. Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Carolina Reyes, PhD, Kenneth Wilhelm, MD, Tania Krivasi, MSc, David L. Veenstra, PharmD, PhD

Blood (2016) 128 (22): 3605.

https://doi.org/10.1182/blood.V128.22.3605.3605

Published: 2016

Journal Articles

Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States

Matthew J. Matasar, MD MS, Stacey Dacosta Byfield, PhD MPH, Cori Blauer-Peterson, MPH, Melissa Montez, PharmD, Carolina Reyes, PhD, Anthony Masaquel, PhD MPH

Blood (2016) 128 (22): 5928.

https://doi.org/10.1182/blood.V128.22.5928.5928

Published: 2016

Journal Articles

Are There Differences in Treatment Patterns, Cost, and Quality Indicators By Site of Care for First Line Treatment for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NHL/CLL)?

Adrianne W Casebeer, MPP, MS, PhD, Sari Hopson, MSPH, PhD, Dana A Drzayich Jankus, MS, Zhuliang Tao, MSPH, Stephen Stemkowski, MHA, PhD, Andrew Howe, PharmD, BA, Jeffrey Patton, MD, Art Small, MD, Anthony Masaquel, MPH, PhD

Blood (2015) 126 (23): 3298.

https://doi.org/10.1182/blood.V126.23.3298.3298

Published: 2015

NARROW

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Introduction of Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 Lines of Systemic Therapy Results in Cost Savings to the Healthcare System Based on a United States Budget Impact Analysis

Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis

Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)

Factors Associated with Overall Survival in Follicular Lymphoma Patients Who Are Eligible for Maintenance Therapy

Treatment Practices and Outcomes in Older Adults with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the Veterans Health Administration

What Are Patients' Preferences and Satisfaction Regarding Modes of Administration for the Treatment of Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma (FL)?

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States

Are There Differences in Treatment Patterns, Cost, and Quality Indicators By Site of Care for First Line Treatment for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NHL/CLL)?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only